AU2013365796B2 - Stabilized insulin-like growth factor polypeptides - Google Patents

Stabilized insulin-like growth factor polypeptides Download PDF

Info

Publication number
AU2013365796B2
AU2013365796B2 AU2013365796A AU2013365796A AU2013365796B2 AU 2013365796 B2 AU2013365796 B2 AU 2013365796B2 AU 2013365796 A AU2013365796 A AU 2013365796A AU 2013365796 A AU2013365796 A AU 2013365796A AU 2013365796 B2 AU2013365796 B2 AU 2013365796B2
Authority
AU
Australia
Prior art keywords
deleted
igf
amino acids
amino acid
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013365796A
Other languages
English (en)
Other versions
AU2013365796A1 (en
Inventor
Mara Fornaro
Thomas Huber
Mauro Zurini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013365796(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013365796A1 publication Critical patent/AU2013365796A1/en
Application granted granted Critical
Publication of AU2013365796B2 publication Critical patent/AU2013365796B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013365796A 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides Ceased AU2013365796B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
US61/738,475 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (2)

Publication Number Publication Date
AU2013365796A1 AU2013365796A1 (en) 2015-05-28
AU2013365796B2 true AU2013365796B2 (en) 2017-03-30

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013365796A Ceased AU2013365796B2 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Country Status (36)

Country Link
US (1) US10167329B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626735A1 (cg-RX-API-DMAC7.html)
JP (1) JP6499080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102182523B1 (cg-RX-API-DMAC7.html)
CN (1) CN105121462B (cg-RX-API-DMAC7.html)
AP (1) AP2015008440A0 (cg-RX-API-DMAC7.html)
AU (1) AU2013365796B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013708B1 (cg-RX-API-DMAC7.html)
CA (1) CA2894976C (cg-RX-API-DMAC7.html)
CL (1) CL2015001708A1 (cg-RX-API-DMAC7.html)
CR (2) CR20200079A (cg-RX-API-DMAC7.html)
CU (1) CU24308B1 (cg-RX-API-DMAC7.html)
CY (1) CY1122309T1 (cg-RX-API-DMAC7.html)
DK (1) DK2935320T3 (cg-RX-API-DMAC7.html)
EA (1) EA034356B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15031046A (cg-RX-API-DMAC7.html)
ES (1) ES2756330T3 (cg-RX-API-DMAC7.html)
GT (1) GT201500168A (cg-RX-API-DMAC7.html)
HR (1) HRP20191965T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047386T2 (cg-RX-API-DMAC7.html)
IL (1) IL239387A0 (cg-RX-API-DMAC7.html)
LT (1) LT2935320T (cg-RX-API-DMAC7.html)
MA (1) MA38153B1 (cg-RX-API-DMAC7.html)
MX (1) MX363021B (cg-RX-API-DMAC7.html)
MY (1) MY174820A (cg-RX-API-DMAC7.html)
NZ (1) NZ708091A (cg-RX-API-DMAC7.html)
PE (2) PE20200894A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501271A1 (cg-RX-API-DMAC7.html)
PL (1) PL2935320T3 (cg-RX-API-DMAC7.html)
PT (1) PT2935320T (cg-RX-API-DMAC7.html)
RS (1) RS59545B1 (cg-RX-API-DMAC7.html)
SA (1) SA515360603B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201503782PA (cg-RX-API-DMAC7.html)
SI (1) SI2935320T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014097116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052123A1 (en) * 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
KR20180137487A (ko) * 2016-03-04 2018-12-27 샤이어 휴먼 지네틱 테라피즈 인크. 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3813861A4 (en) * 2018-06-27 2022-08-10 Juvena Therapeutics, Inc. HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
EP4652282A2 (en) * 2023-11-14 2025-11-26 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2006074390A2 (en) * 2005-01-07 2006-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
WO2007146689A2 (en) * 2006-06-09 2007-12-21 Novartis Ag Stabilized insulin-like growth factor polypeptides
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
ES2784926T3 (es) 2007-12-21 2020-10-02 Novartis Ag Vector de expresión de mamífero
HUE035240T2 (hu) 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2006074390A2 (en) * 2005-01-07 2006-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
WO2007146689A2 (en) * 2006-06-09 2007-12-21 Novartis Ag Stabilized insulin-like growth factor polypeptides
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UNIPROT Accession No. P01344, 21 July 1986 *

Also Published As

Publication number Publication date
US10167329B2 (en) 2019-01-01
CN105121462A (zh) 2015-12-02
PT2935320T (pt) 2019-11-15
EP2935320B1 (en) 2019-08-21
BR112015013708B1 (pt) 2022-10-18
PE20151612A1 (es) 2015-11-19
CN105121462B (zh) 2019-08-02
MY174820A (en) 2020-05-17
RS59545B1 (sr) 2019-12-31
CA2894976C (en) 2022-10-04
PE20200894A1 (es) 2020-09-08
WO2014097116A1 (en) 2014-06-26
ES2756330T3 (es) 2020-04-27
EP2935320A1 (en) 2015-10-28
EA034356B1 (ru) 2020-01-30
CU20150064A7 (es) 2016-02-29
CL2015001708A1 (es) 2015-08-28
HUE047386T2 (hu) 2020-04-28
NZ708091A (en) 2018-03-23
EP3626735A1 (en) 2020-03-25
KR102182523B1 (ko) 2020-11-25
SG11201503782PA (en) 2015-06-29
DK2935320T3 (da) 2019-11-18
MA38153B1 (fr) 2018-06-29
PL2935320T3 (pl) 2020-03-31
SI2935320T1 (sl) 2019-12-31
SA515360603B1 (ar) 2020-07-26
BR112015013708A2 (pt) 2017-11-14
CR20150324A (es) 2015-08-10
PH12015501271B1 (en) 2015-08-24
MA38153A1 (fr) 2016-06-30
AU2013365796A1 (en) 2015-05-28
CY1122309T1 (el) 2021-01-27
KR20150095879A (ko) 2015-08-21
EA201591165A1 (ru) 2015-11-30
GT201500168A (es) 2016-01-21
AP2015008440A0 (en) 2015-05-31
JP2016501025A (ja) 2016-01-18
CR20200079A (es) 2020-03-21
CA2894976A1 (en) 2014-06-26
ECSP15031046A (es) 2019-03-29
TN2015000182A1 (en) 2016-10-03
MX2015007932A (es) 2015-10-05
PH12015501271A1 (en) 2015-08-24
HRP20191965T1 (hr) 2020-01-24
MX363021B (es) 2019-03-05
IL239387A0 (en) 2015-07-30
JP6499080B2 (ja) 2019-04-10
CU24308B1 (es) 2018-01-10
US20150329614A1 (en) 2015-11-19
LT2935320T (lt) 2019-11-11
HK1212712A1 (en) 2016-06-17

Similar Documents

Publication Publication Date Title
AU2013365796B2 (en) Stabilized insulin-like growth factor polypeptides
US10253103B2 (en) Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1
TWI687435B (zh) 用於ｔ調節細胞之擴展的介白素-２突變蛋白
JP6621478B2 (ja) 一本鎖Ｆｃ融合タンパク質
CN117736297A (zh) April和baff抑制性免疫调节蛋白及其使用方法
KR102753264B1 (ko) C1 에스테라제 억제제 융합 단백질 및 이의 용도
WO2022169913A2 (en) Synthetic degrader system for targeted protein degradation
KR20230025673A (ko) CD3 및 FolR1에 결합하는 항체
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
US11427627B2 (en) Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3808771A1 (en) Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
CN111164101B (zh) 甲状腺素视黄质运载蛋白免疫球蛋白融合体
HK1212712B (en) Stabilized insulin-like growth factor polypeptides
US12221488B2 (en) APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01
CA3128027A1 (en) Parathyroid hormone variants
TW202436623A (zh) 用於表現位於ｎ端之甲硫胺酸已經除去的融合蛋白之卡匣及其用途
WO2024041477A1 (zh) 多结构域融合蛋白的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)